Sagimet Biosciences Announces FDA Clearance for Phase 3 Acne Trial

What Happened

• On August 13, 2026, Sagimet Biosciences, Inc. (NASDAQ: SGMT) filed a Form 8-K (Item 8.01) announcing that the U.S. Food and Drug Administration cleared the company’s Investigational New Drug (IND) application and issued a "Study May Proceed" letter.
• The clearance allows Sagimet to initiate a Phase 3 clinical trial of denifanstat, a fatty acid synthase inhibitor, for the treatment of moderate to severe acne.

Key Details

• Filing date: August 13, 2026 (Form 8-K, Item 8.01).
• Agency action: FDA cleared the IND and issued a "Study May Proceed" letter.
• Study: Phase 3 clinical trial of denifanstat for moderate to severe acne.
• Drug: denifanstat — fatty acid synthase inhibitor (development candidate).

Why It Matters

• FDA IND clearance and a "Study May Proceed" letter are regulatory milestones that permit Sagimet to begin a pivotal Phase 3 trial in the U.S., a central step toward potential future approval if trial results are positive.
• For investors, this advances Sagimet’s clinical development timeline for denifanstat and may influence upcoming newsflow (trial start, enrollment progress, and future data readouts) and potential milestone events.